Type II [3H]estradiol binding site antagonists: Inhibition of normal and malignant prostate cell growth and proliferation

International Journal of Oncology

Volumn 12, Issue 5, 1998, Pages 1127-1135

  Markaverich, Barry M ^a   Alejandro, Mary Ann ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cyclohexanones; Prostatic cancer; Type II 3H estradiol binding sites

Indexed keywords

2,6 BIS[(3 METHOXY 4 HYDROXYPHENYL)METHYLENE]CYCLOHEXANONE; CYCLOVALONE; ESTRADIOL RECEPTOR; UNCLASSIFIED DRUG; CYCLOHEXANONE DERIVATIVE; CYQUALON; ESTRADIOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GRAFT; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; MALE; MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BODY WEIGHT; CELL CULTURE; CELL DIVISION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; HISTOLOGY; METABOLISM; NUDE MOUSE; ORAL DRUG ADMINISTRATION; ORGAN SIZE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RAT; SEMINAL VESICLE; TESTIS;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; CELL DIVISION; CYCLOHEXANONES; ESTRADIOL; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, BIOLOGICAL; ORGAN SIZE; PROSTATE; PROSTATIC NEOPLASMS; RATS; RECEPTORS, ESTRADIOL; SEMINAL VESICLES; TESTIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031594278     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.5.1127     Document Type: Article

References (54)

1. Ho S and Yu M: Selective increase in type II estrogen-binding sites in the dysplastic dorsolateral prostates of noble rats. Cancer Res 53: 528-532, 1993.
2. 3H]estradiol binding sites and prostatic cancer cell proliferation. Int J Oncol 11: 1311-1319, 1997.
3. Eriksson H, Upchurch S, Hardin JW, Peck EJ Jr and Clark JH: Heterogeneity of estrogen receptors in the cytosol and nuclear fractions of the rat uterus. Biochem Biophys Res Commun 81: 1-7, 1978.
4. Markaverich BM and Clark JH: Two binding sites for estradiol in rat uterine nuclei: relationship to uterotropic response. Endocrinology 105: 1458-1462, 1979.
5. 3H]estradiol binding in normal and malignant tissues. Cancer Res 44: 1515-1519, 1984.
6. Watson CS, Medina D and Clark JH: Characterization of progesterone receptors, estrogen receptors and estrogen (type II)-binding sites in the hormone-independent variant of the MXT-3590 mouse mammary tumor. Endocrinology 107: 1432-1437, 1982.
7. Syne JS, Markaverich BM, Clark JH and Panko WB: Estrogen binding sites in the nucleus of normal and malignant human tissue: characteristics of the multiple nuclear binding sites. Cancer Res 42: 4449-4454, 1982.
8. Syne JS, Markaverich BM, Clark JH and Panko WB: Estrogen binding sites in the nucleus of normal and malignant human tissue: optimization of an exchange assay for the measurement of specific binding. Cancer Res 42: 4443-4448, 1982.
9. Markaverich BM, Upchurch S and Clark JH: Progesterone and dexamethasone antagonism of uterine growth: a role for a second nuclear estrogen binding site for estradiol in estrogen action. J Steroid Biochem 14: 125-132, 1981.
10. Markaverich BM, Upchurch S, McCormack SA, Classer SR, and Clark JH: Differential stimulation of uterine cells by nafoxidine and clomiphene: relationship between nuclear estrogen receptors and type II estrogen binding sites and cellular growth. Biol Reprod 24: 171-181, 1981.
11. Karoum F: On the origin of central and peripheral p-hydroxyphenylacetic acid in rats: a comparison with metabolites of biogenic amines other than p-tyramine. Biogenic Amines 2: 269-282, 1985.
12. Griffiths LA and Smith GE: Metabolism of apigenin and related compounds in the rat. Biochem J 128: 901-911, 1972.
13. Markaverich BM, Gregory RR, Alejandro MA, Clark JH, Johnson GA and Middleditch BS: Methyl p-hydroxyphenyl-Iactate: an inhibitor of cell proliferation and an endogenous ligand for nuclear type II binding sites. J Biol Chem 263: 7203-7210, 1988.
14. Markaverich B, Adams N, Roberts R, Alejandro M and Clark J: Cytosol type II sites in the rat uterus: interaction with an endogenous ligand. J Steroid Biochem 28: 599-608, 1987.
15. 3H]estradiol binding in rat uterine nuclei. J Biol Chem 258: 11663-11671, 1983.
16. Markaverich BM, Gregory RR, Alejandro MA, Varma RS, Johnson GA and Middleditch BS: Estrogen regulation of methyl p-hydroxyphenyllactate hydrolysis: correlation with estrogen stimulation of rat uterine growth. J Steroid Biochem 33: 867-876, 1989.
17. Markaverich B, Gregory R, Alejandro M, Kittrell F, Medina D, Clark J, Varma M and Varma R: Methyl p-hydroxyphenyl-lactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res 50: 1470-1478, 1990.
18. Markaverich BM, Schauweker TH, Gregory RR, Varma M, Kittrell FS, Medina D and Varma RS: Nuclear type II sites and malignant cell proliferation: inhibition by benzylidenecyclo-hexanones. Cancer Res 52: 2482-2488, 1992.
19. Carbone A, Ranelletti FO, Rinelli A, Vecchio FM, Lauriola L, Piantelli M and Capelli A: Type II estrogen receptor in the papillary cystic tumor of the pancreas. Am J Clin Pathol 92: 572-576, 1989.
20. Densmore CL, Markaverich BM, O'Malley BW and Clark JH: Characterization and partial purification of an estrogen type II binding site in chick oviduct cytosol. Biochemistry 28: 7788-7796, 1989.
21. Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, Bonanno G, deVincenzo R, Ferrandina G, Rumi C, Larocca LM and Manusco S: Inhibitory effects of quercetin on OVCA 433 cells and the presence of type II oestrogen binding sites in primary ovarian tumors and cultured cells. Br J Cancer 62: 942-946, 1990.
22. Piantelli M, Ricci R, Larocca L, Capelli A, Rizzo S, Scambia G and Ranelletti F: Type II estrogen binding sites in human colorectal carcinoma. J Clin Pathol 43: 1004-1006, 1990.
23. Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, Rumi C, Battaglia F, La Rocca LM, Capelli A and Manusco S: Type II estrogen binding sites in a lymphoblastoic cell line and growth inhibitory effects of estrogen, anti-estrogen and bioflavonoids. Int J Cancer 46: 1112-1116, 1990.
24. 3H]estradiol binding sites in MCF-7 human breast cancer cells: binding interactions with 2, 6-bis([3,4-dihydroxyphenyl]-methylene)-cyclohexanone esters and inhibition of cell proliferation. Int J Oncol 4: 1291-1300, 1994.
25. Clark JH and Markaverich BM: Heterogeneity of estrogen binding sites on the nuclear matrix. Alan R. Liss, Inc., New York, pp259-269, 1980.
26. Beato M and Sanchez-Pacheco A: Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 17: 587-609, 1996.
27. Clark JH and Markaverich BM: The agonistic and antagonistic actions of estriol. J Steroid Biochem 1005-1013, 1984.
28. Clark JH, Williams M, Upchurch S, Eriksson H, Helton E and Markaverich BM: Effects of estradiol-17α on nuclear occupancy of the estrogen receptor, stimulation of nuclear type II sites and uterine growth. J Steroid Biochem 16: 323-328, 1982.
29. 3H]estradiol exchange. Endocrinology 109: 62-69, 1981.
30. Markaverich BM, Schauweker TH, Gregory RR, Varma RS, Varma M, Kittrell FS and Medina D: Combination therapy with a nuclear type II site antagonist and 5-fluorouracil: inhibition of mammary tumor growth. Int J Oncol 2: 385-392, 1993.
31. Ho S, Viccione T and Yu M: In vitro and in vivo inhibition of nuclear type II estrogen binding sites in the dorsolateral prostate of noble rats. J Steroid Biochem Mol Biol 46: 489-495, 1993.
32. Ho S-M and Yu M: Hormonal regulation of nuclear type II estrogen binding sites in the dorsolateral prostate of noble rats. J Steroid Biochem Mol Biol 52: 233-238, 1995.
33. Ho SM, Leav I, Merk FB, Kwan PW and Ziar J: Induction of atypical hyperplasia, apoptosis, and type II estrogen-binding sites in the ventral prostates of noble rats treated with testosterone and pharmacologic doses of estradiol-17 beta. Lab Invest 73: 356-365, 1995.
34. 3H]estradiol binding site antagonists: inhibiton of normal and malignant prostate cell growth and proliferation. Cancer Res (In press).
35. Markaverich BM, Webb B, Densmore CL and Gregory RR: Effects of coumestrol on estrogen receptor function and uterine growth in ovariectomized rats. Environ Health Perspect 103: 574-581, 1995.
36. Markaverich BM, Roberts RR, Alejandro MA, Johnson GA, Middleditch BS and Clark JH: Bioflavonoid interactions with rat uterine type II binding sites and cell crowth inhibition. J Steroid Biochem 29: 71-78, 1988.
37. Burton K: A study on the conditions and mechanism of the diphenylamine reaction for colorimetric estimation of deoxyribonucleic acid. Biochem J 62: 315-323, 1956.
38. Sedlacek H, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A and Sausville E: Flavopiridol (L868275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9: 1143-1168, 1996.
39. Snyder BW, Winneker RC and Batzold FH: Endocrine profile of WIN 49596 in the rat: a novel androgen receptor antagonist. J Steroid Biochem 33: 1127-1132, 1989.
40. Winneker RC, Wagner MM and Batzold FH: Studies of the mechanism of action of WIN 49596: a steroidal androgen receptor antagonist. J Steroid Biochem 33: 1133-1138, 1989.
41. Gingrich J, Barrios R, Morton R, Boyce B, deMayo F, Finegold M, Angelopoulou R, Rosen J and Greenberg N: Metastatic prostate cancer in a transgenic mouse. Cancer Res 56: 4096-4102, 1996.
42. Greenberg N, deMayo F, Sheppard P, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd J, Duckwork M, Rosen J and Matusik R: The rat probasin gen promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 8: 230-239, 1994.
43. Greenberg N, deMayo F, Finegold M, Medina D, Tilley W, Aspinall J, Guhna G, Donjacour A, Matusik R and Rosen J: Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443, 1995.
44. Markaverich BM and Gregory RR: Preliminary characterization and partial purification of rat uterine nuclear type II sites. Biochem Biophys Res Commun 177: 1283-1290, 1991.
45. Poirot M, Chailleux C, Bayard F and Faye J-C: Cytosolic type II estrogen binding site in rat uterus: specific photolabeling with estrone. J Receptor Res 12: 217-231, 1992.
46. Gray WG, Biswas EE, Bashirelahi N and Biswas SB: A low-affinity estrogen binding site in pregnant rat uteri: analysis and partial purification. Proc Natl Acad Sci USA 91: 11502-11506, 1994.
47. Garai J and Clark JH: Estrogen affinity crosslinking to tyrosinase-like immunoreactive protein of rat uterine nuclear extracts. J Steroid Biochem Mol Biol (In press).
48. Densmore CL, Schauweker TS, Gregory RR, Webb B, Garcia E and Markaverich BM: Chromatographic resolution of the type II estrogen binding site and a tyrosinase-like enzymatic activity from rat uterine nuclei. Steroids 59: 282-287, 1994.
49. Maybruck WM and Markaverich BM: Detection of esterase activity in nondenaturing NuSieve agarose gels from the reliant gel system. Resolutions, FMC BioProducts 11: 7, 1995.
50. Maybruk WM: Partial purification and characterization of methyl-p-hydroxyphenyllactate esterase in rat uterine cytosol. Steroids 62: 321-330, 1997.
51. Clark JH, Paszko Z and Peck EJ Jr: Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol. Endocrinology 100: 91-96, 1977.
52. Markaverich BM, Roberts RR, Alejandro MA and Clark JH: The effect of low dose continuous exposure to estradiol on the estrogen receptor (type I) and nuclear type II sites. Endocrinology 114: 814-820, 1984.
53. O'Connor P, Jackman J, Jondle D, Bhatia K, Magrath I and Kohn R: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53: 4776-4780, 1993.
54. Steele RGD and Torrie JH: Principles and procedures of statistics. McGraw and Hill, Inc., New York, 1960.